Spotlight on Gastroenterology

Credits: 1.00 CME / CE
Thinking Beyond the Baby Boomers: Critical Considerations for HCV Identification and Care
Dawn Fishbein, MD, MS
Med-IQ

Thinking Beyond the Baby Boomers: Critical Considerations for HCV Identification and Care

Start

Providership Statement

This activity was developed by Med-IQ in collaboration with MedStar Health Research Institute.

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour for nurses
Release Date: December 22, 2017
Expiration Date: December 21, 2018
1 hour to complete

Activity Description

This CME/CE publication reviews guideline recommendations and current evidence for hepatitis C virus testing in asymptomatic patients and discusses the practical application of those guidelines in clinical practice. This activity also explores areas of emerging evidence and focus, particularly the management of women of childbearing potential and patients with substance use disorder.

Faculty

Dawn Fishbein, MD, MS
Scientific Director, Viral Hepatitis Research
MedStar Health Research Institute
Recruitment Module Director
Georgetown Howard Universities Center for Clinical and Translational Science CTSA
Associate Chair for Research, Department of Medicine
MedStar Washington Hospital Center
Washington, DC


Accreditation Statement

Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation/Designation Statements (ANCC)

Med-IQ is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This nursing activity has been approved for up to 1.0 contact hour.

Others Credit Information

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation

To receive credit, complete the pre-survey, read the introductory CME/CE material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Contact Information for Questions about the Activity

For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Copyright

© 2017 Med-IQ, LLC

Gastroenterology Presentations

1.25 CME
Vindico
Therapeutic Drug Monitoring in Crohn’s Disease: Personalized Approaches for Treatment Optimization

Therapeutic Drug Monitoring in Crohn’s Disease: Personalized Approaches for Treatment Optimization

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credits
Released: August 31, 2018
Expires: August 31, 2019
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by Vindico Medical Education

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the treatment of patients with Crohn's disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate the mechanisms behind primary and secondary non-response to biologic agents in the treatment of Crohn’s disease.
  • Utilize strategies that mitigate the loss of response to a biologic agent in Crohn’s disease.
  • Incorporate new guidelines and best practices regarding the use of therapeutic drug monitoring in the management of Crohn’s disease.
  • Apply new evidence regarding the safety and efficacy of biologic agents used in the long-term management of Crohn’s disease.

Activity Description

Despite the proven therapeutic efficacy of anti-tumor necrosis factor (TNF) agents, treatment failures due to primary nonresponse or secondary loss of response (LOR) can occur in patients with Crohn’s disease. Approximately 10% to 20% of patients with inflammatory bowel disease have been reported to be unresponsive to induction treatment with anti-TNF agents. A significant portion of those patients who initially respond to anti-TNF treatment lose response over time, with an annual increased risk of 13% to 24%. Several distinct mechanisms for secondary LOR have been suggested, including the formation of antidrug antibodies. In clinical practice, therapeutic drug monitoring (TDM) has been shown to be clinically useful, cost-effective, and associated with improved clinical and endoscopic outcomes. The use of TDM in patients with Crohn’s disease provides a personalized approach to optimize treatment, with new guidelines for its use now available. In addition, the measurement of drug concentrations and antidrug antibodies can be used to improve treatment outcomes. This case-based activity is intended to help clinicians integrate scientific advances into real-world practice settings, assess the causes of LOR, incorporate new guidelines into practice, and effectively utilize TDM for patients receiving biologic agents.

Agenda

  • Decisions, Decisions…Primary and Secondary Loss of Response to Biologics in Crohn’s Disease
  • Therapeutic Drug Monitoring in the Management of Crohn’s Disease
  • Case Presentation – Loss of Response, TDM, and Dose Optimization

Faculty

Bruce E. Sands, MD, MS (Activity Chair)
Chief, Dr. Henry D. Janowitz Division of Gastroenterology 
Dr. Burrill B. Crohn Professor of Medicine 
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System 
New York, NY

Consulting Fee: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Boehringer-Ingelheim, Capella Bioscience, Celgene, EnGene, Ferring, Gilead, Janssen, Lilly, Lyndra, MedImmune, Oppilan, Otsuka, Palatin Technologies, Pfizer, Rheos Medicines, Seres Therapeutics, Takeda, Target PharmaSolutions, Theravance, TiGenix, Vivelix
Contracted Research: Celgene, Takeda


Edward V. Loftus Jr., MD
Professor of Medicine 
Consultant, Division of Gastroenterology and Chair, Inflammatory Bowel Disease Interest Group 
Mayo Clinic 
Rochester, MN

Consulting Fee: AbbVie, Amgen, Celgene, Celltrion Healthcare, Eli Lilly, Janssen, Napo Pharma, Pfizer, Takeda, UCB
Contracted Research: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Pfizer, MedImmune, Receptos, Robarts Clinical Trials, Seres Therapeutics, Takeda, UCB


Marla Dubinsky, MD
Chief, Pediatric Gastroenterology and Hepatology
Co-Director, the Susan and Leonard Feinstein IBD Clinical Center
Icahn School of Medicine at Mount Sinai
New York, NY

Consulting Fee: AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, Janssen, Pfizer, Prometheus, Salix, Shire, Takeda, UCB


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.  Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from UCB, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME
The Postgraduate Institute for Medicine
IBD In Clinical Practice: Malnutrition Update For Healthcare Providers 2018

IBD In Clinical Practice: Malnutrition Update For Healthcare Providers 2018

Start

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine, the Crohn's & Colitis Foundation, and RMEI Medical Education, LLC. This activity is supported by an independent medical educational grant from Nestlé Health Science.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: March 29, 2018
Expires: March 29, 2019
1 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and gastroenterology nurse practitioners (NPs) and physician assistants (PAs) who manage patients with IBD.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Summarize the clinical significance of malnutrition and related complications
  • Identify IBD patients who are at risk for malnutrition by using the Malnutrition Universal Screening Tool (MUST)
  • Describe screening, assessment, and intervention/monitoring for malnutrition in IBD patients as outlined by the CCFA IBD Nutrition Care Pathway
  • Engage IBD patients who are at risk or have malnutrition in their healthcare by implementing effective shared decision making strategies

Faculty

Caroline Hwang, MD
Caroline Hwang, MD
Assistant Professor of Clinical Medicine
Medical Director, Inflammatory Bowel Disease Center
Keck/University of Southern California School of Medicine
Los Angeles, CA


Kelly Issokson, MS, RD, CNSC
Kelly Issokson, MS, RD, CNSC
Clinical Dietitian
Cedars-Sinai Medical Center
Los Angeles, CA


Gil Y. Melmed, MD, MS
Gil Y. Melmed, MD, MS
Director of Clinical Inflammatory Bowel Disease (IBD) 
Cedars-Sinai Medical Center
Associate Professor of Medicine
David Geffen University of California, Los Angeles (UCLA) School of Medicine
Los Angeles, CA


Aline Charabaty, MD (Reviewer)
Aline Charabaty, MD (Reviewer)
Associate Professor of Medicine
Director, IBD Center
Medstar Georgetown University Hospital
Washington, DC


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Caroline Hwang, MD, has affiliations with UCB (Consulting Fees); Janssen, Nestlé Health Science (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents); AbbVie, Celgene, Eli-Lilly (Contracted Research).
  • Kelly Issokson, MS, RD, CNSC, has no affiliations with commercial interests to disclose.
  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Celgene, Janssen, Medtronic, Pfizer, Takeda, UCB (Consulting fees).
  • Aline Charabaty, MD, has affiliations with AbbVie (Consulting Fees); AbbVie, Janssen, Takeda (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents); Janssen (Contracted Research).

Crohn’s & Colitis Foundation of America

  • Sudha Sarode, MSPH, has no affiliations with commercial interests to disclose.

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Faith Reidenbach, CHCP, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Joint Accreditation Statement

Accreditation Council for Pharmacy Education In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine, the Crohn's & Colitis Foundation, and RMEI Medical Education, LLC. This activity is supported by an independent medical educational grant from Nestlé Health Science.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware / Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.00 CME
Crohn’s & Colitis Foundation of America
IBD in Clinical Practice: Diagnosis and Medical Treatment - 2018

IBD in Clinical Practice: Diagnosis and Medical Treatment - 2018

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: May 3, 2018
Expires: May 2, 2019
1 hour to complete

Target Audience

Physicians, gastroenterologists, nurse practitioners, and physician assistants

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Describe indications for and interpretation of diagnostic testing in inflammatory bowel diseases
  • Apply principles of therapeutic management according to clinical symptoms, duration, and severity of disease

Jointly Provided By

This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation.

Faculty

Miguel Regueiro, MD
Miguel Regueiro, MD
Chair, Department of Gastroenterology and Hepatology
Professor, Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

Dr. Regueiro has affiliations (Consultant) with AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres, Takeda, UCB; (Research) with AbbVie, Janssen, Takeda; (Unrestricted Educational Grants) with AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB.


Hans Herfarth, MD, PhD
Hans Herfarth, MD, PhD
Professor of Medicine
University of North Carolina
Chapel Hill, NC

Dr. Herfarth has affiliations (Consultant) with Allergan, Boehringer, Celltrion, Lycera, Merck, Pfizer, Samsung, Seres.


Conflict of Interest Policy/Disclosure Statement

Authors disclosure of relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing healthcare goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this educational activity have relevant financial relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other healthcare professionals are awarded .10 continuing education units (CEUs), which are equal to 1.0 contact hour. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA Category 1 Credit™.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 65% or higher on the post-test to receive credit for this activity. You will have 3 attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is supported by educational grants from AbbVie Inc., Salix Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.50 CME
Crohn’s & Colitis Foundation of America
IBD in Clinical Practice: Long-term Disease Management and Surgery - 2018

IBD in Clinical Practice: Long-term Disease Management and Surgery - 2018

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: May 3, 2018
Expires: May 2, 2019
0.5 hour to complete

Target Audience

Physicians, gastroenterologists, nurse practitioners, and physician assistants

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Decide which medical treatment to use in acute IBD flares and for long-term disease management
  • Identify IBD characteristics for which surgery is indicated

Jointly Provided By

This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation.

Faculty

Miguel Regueiro, MD
Miguel Regueiro, MD
Chair, Department of Gastroenterology and Hepatology
Professor, Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

Dr. Regueiro has affiliations (Consultant) with AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres, Takeda, UCB; (Research) with AbbVie, Janssen, Takeda; (Unrestricted Educational Grants) with AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB.


Hans Herfarth, MD, PhD
Hans Herfarth, MD, PhD
Professor of Medicine
University of North Carolina
Chapel Hill, NC

Dr. Herfarth has affiliations (Consultant) with Allergan, Boehringer, Celltrion, Lycera, Merck, Pfizer, Samsung, Seres.


Conflict of Interest Policy/Disclosure Statement

Authors disclosure of relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing healthcare goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this educational activity have relevant financial relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other healthcare professionals are awarded .05 continuing education units (CEUs), which are equal to 0.5 contact hour. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credit™.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 75% or higher on the post-test to receive credit for this activity. You will have 3 attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is supported by educational grants from Salix Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.00 CME
Vindico
Improving the Continuum of Care in Patients with Inflammatory Bowel Disease: A Patient Simulation Activity

Improving the Continuum of Care in Patients with Inflammatory Bowel Disease: A Patient Simulation Activity

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: February 15, 2018
Expires: February 14, 2019
1 hour to complete

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Simulation-services provided by Syandus

Support Statement

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Activity Chair

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA

Disclosure:
Royalty: SLACK Incorporated;
Consulting Fees: Abbott/AbbVie, Actavis, Alaven, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Pfizer, Prometheus, Romark, Salix, Santarus, Shire, Takeda, UCB;
Contracted Research: Ferring, Prometheus, Salix, Santarus, Shire, UCB;
Research Grant (paid to institution): Janssen Orthobiotech;
Author Honoraria: McMahon Publishing, Up to Date;
Editor Honoraria: Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media.



Faculty

Meenakshi Bewtra, MD, PhD, MPH
Assistant Professor of Medicine and Epidemiology
Center for Clinical Epidemiology and Biostatistics
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosure:
Contracted Research: GlaxoSmithKline, Takeda.



Nabeel Khan, MD
Assistant Professor of Clinical Medicine
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania
Director of Gastroenterology
Philadelphia VA Medical Center
Philadelphia, PA

No relevant financial relationships to disclose.


Reviewer

Ronald Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 15, 2018 to February 14, 2019.

How To Participate in this Activity and Obtain CME Credit

  • Read the target audience, learning objectives, and faculty disclosures.
  • Launch the simulation from the link provided on GastroCE.com on a PC, Mac, tablet, or plus-size phone.
  • Complete the pretest and launch the first simulation scenario. Interact appropriately to satisfy each objective to unlock the next objective. The simulation will track your progress until all scenario objectives and assessment components are complete. You can exit the simulation and it will save your progress so that you can return to finish at a later time.
  • As you successfully complete more scenarios (2 total), you will qualify for increasing levels of CE credit (ranging from 0.5 to 1.00 credits). Click or tap "Credit" to determine your CE credit status and receive credit. Upon successful completion of the evaluation, you will receive a certificate of credit immediately via the browser.

Overview

Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1 to 1.3 million people in the United States. Improvement in the care of patients with IBD is needed, as evidenced by a recent study of insurance claims that showed approximately 80% of 32,883 patients with IBD received suboptimal therapy. The outcomes of patients with IBD are diminished by multiple factors, including uncertainty about approaches to diagnosis, assessment, and treatment, as well as a lack of knowledge about available therapies.

To meet the persistent challenges associated with IBD management, health care professionals must be knowledgeable about the evidence-based and expert-recommended strategies for the treatment of patients with IBD to avoid disease flares, prevent structural damage and disability, as well as restore quality of life. In this virtual IBD patient management simulator, an authentic in-office setting with patient interaction will be presented. This simulation will allow authentic practice in the management of a patient with IBD, including determining the appropriate therapy for IBD based on the type and severity.

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the treatment of patients with IBD.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Analyze endoscopic and histologic findings that are characteristic of specific types of inflammatory bowel disease.
  • Apply the safety and efficacy of conventional and new treatments when determining the appropriate therapy for inflammatory bowel disease, based upon type and severity.
  • Incorporate therapeutic drug monitoring, stool markers, and the assessment of mucosal healing in monitoring inflammatory bowel disease as well as in response to treatment, to better predict exacerbations.

Copyright Statement

This CME simulation activity is licensed to Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Copyright © 2018 Syandus Inc and Vindico Medical Education. All rights reserved. No part of this simulation activity may be reproduced without written permission from Vindico Medical Education and Syandus Inc. The material presented in this Vindico Medical Education continuing medical education activity does not necessarily reflect the views and opinions of Vindico Medical Education or Syandus Inc. Neither Vindico Medical Education, Synadus Inc, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME / CE
Med-IQ
Thinking Beyond the Baby Boomers: Critical Considerations for HCV Identification and Care

Thinking Beyond the Baby Boomers: Critical Considerations for HCV Identification and Care

Start

Providership Statement

This activity was developed by Med-IQ in collaboration with MedStar Health Research Institute.

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour for nurses
Release Date: December 22, 2017
Expiration Date: December 21, 2018
1 hour to complete

Activity Description

This CME/CE publication reviews guideline recommendations and current evidence for hepatitis C virus testing in asymptomatic patients and discusses the practical application of those guidelines in clinical practice. This activity also explores areas of emerging evidence and focus, particularly the management of women of childbearing potential and patients with substance use disorder.

Faculty

Dawn Fishbein, MD, MS
Scientific Director, Viral Hepatitis Research
MedStar Health Research Institute
Recruitment Module Director
Georgetown Howard Universities Center for Clinical and Translational Science CTSA
Associate Chair for Research, Department of Medicine
MedStar Washington Hospital Center
Washington, DC


Accreditation Statement

Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation/Designation Statements (ANCC)

Med-IQ is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This nursing activity has been approved for up to 1.0 contact hour.

Others Credit Information

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation

To receive credit, complete the pre-survey, read the introductory CME/CE material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Contact Information for Questions about the Activity

For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Copyright

© 2017 Med-IQ, LLC

1.00 CME / CNE
Med-IQ
On the Road to Elimination: Evaluating and Improving the Continuum of Care for Patients With HCV

On the Road to Elimination: Evaluating and Improving the Continuum of Care for Patients With HCV

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: December 20, 2017
Expires: December 19, 2018
45 minutes to complete

Target Audience

This activity is intended for primary care clinicians.

Activity Description

Significant efforts to improve HCV testing have occurred in recent years. However, if the elimination of the virus is to be possible, then all steps along the HCV care continuum need to be improved. This online publication focuses on evidence-based strategies to eliminate HCV by increasing the number of patients with chronic HCV infection who are diagnosed, treated, and cured.

Statement of Educational Need

Global discussions and goals related to the elimination of viral hepatitis have led to the development of a viral hepatitis elimination action plan by the National Academies of Science, Engineering, and Medicine. In their first report, the National Academies determined that disease elimination, though possible, will take considerable effort and resources. A more realistic shorter-term goal is disease control, which requires a reduction in the disease incidence and better overall care to reduce the downstream patient impact. Despite significant efforts to improve the identification of hepatitis C virus infection in recent years, evidence continues to indicate significant opportunities for better engagement of newly identified patients.

Faculty

Dawn Fishbein, MD, MS
Scientific Director, Viral Hepatitis Research
MedStar Health Research Institute
Recruitment Module Director
Georgetown Howard Universities Center for Clinical and Translational Science CTSA
Associate Chair for Research, Department of Medicine
MedStar Washington Hospital Center
Washington, DC

Providership Statement

This activity was developed by Med-IQ in collaboration with MedStar Health Research Institute.

Accreditation Statement

Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medium/Method of Participation

To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Contact Information for Questions about the Activity

For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email info@med-iq.com.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Copyright

© 2017 Med-IQ, LLC

1.00 CME
University of Cincinnati
Clinical Convergence®: Patient and Provider Perspectives in IBD 2018

Clinical Convergence®: Patient and Provider Perspectives in IBD 2018

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: December 14, 2017
Expires: December 14, 2018
1 hour to complete

Jointly Provided By

   

Target Audience

Gastroenterologists and gastroenterology nurse practitioners (NPs) and PAs

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  2. Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  3. Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  4. Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Activity Description

This unique Clinical Convergence® educational activity integrates healthcare provider and patient perspectives with clinical content that focuses on several aspects of inflammatory bowel disease (IBD) care, including personalized treatment decisions, patient and drug monitoring, and shared decision making.

Based on the proceedings from a live regional half-day symposium for healthcare providers and patients hosted by the Crohn’s & Colitis Foundation, RMEI Medical Education, LLC, and the University of Cincinnati, this activity features three IBD patient case vignettes, challenging interactive questions related to the cases, and audio interaction from the actual patients presented in the vignettes. It is designed to engage learners and offer real-time teaching moments illustrating the potential differences between clinician and patient perceptions of their care and to demonstrate effective care strategies, from the patient perspective.

A handout listing educational resources based on today’s topics of shared decision making, treatment, and monitoring, is available for download at the end of the activity.

Faculty

Millie D. Long, MD, MPH
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Director, Gastroenterology and Hepatology Fellowship Program
University of North Carolina School of Medicine
Chapel Hill, NC

Dr. Long discloses the following relationships with commercial interests:
AbbVie Inc., Pfizer Inc., Takeda Pharmaceuticals USA, Inc., and TARGET PharmaSolutions (Consultant); Takeda Pharmaceuticals USA, Inc. (Research Support); and AbbVie Inc. and UCB (Speaker).


Meenakshi Bewtra, MD, MPH, PhD
Assistant Professor of Medicine, Division of Gastroenterology
Senior Scholar, Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania School of Medicine
Philadelphia, PA

Dr. Bewtra discloses the following relationships with commercial interests:
Janssen Pharmaceuticals, Inc. (Consultant); GlaxoSmithKline and Takeda Pharmaceuticals USA, Inc. (Research Support); and AbbVie Inc. (Speaker).


Derek R. Patel, MD
Clinical Professor of Medicine
Associate Clinical Services Chief
Division of Gastroenterology
University of California, San Diego
San Diego, CA

Dr. Patel discloses the following relationships with commercial interests:
AbbVie Inc. (Consultant) and AbbVie Inc. (Speaker).


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Crohn’s & Colitis Foundation
Sudha Sarode, MSPH, has no relevant relationships to disclose.

RMEI Medical Education, LLC
Sherri Kramer, MD, has no relevant relationships to disclose.
Tania Dickson has no relevant relationships to disclose.
Jessica Hatch has no relevant relationships to disclose.

University of Cincinnati
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, Director, has no relevant relationships to disclose.
Rick E. Ricer, MD, has no relevant relationships to disclose.
Deborah Cole, BS, has no relevant relationships to disclose.

Conflict of Interest Policy / Disclosure Statement

According to the disclosure policy of the University of Cincinnati, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosure will be made at the time of activity.

In accordance with the ACCME Standards for Commercial Support, the speakers for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (eg, paid speaker, employee, paid consultant on a board, and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

The University of Cincinnati designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By completing the curriculum challenge (at the beginning and again at the end of the activity), the pre-test, reviewing the course content, and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1.0 AMA PRA Category 1 Credit™. A statement of credit will be available to print from your user history page.

Users must:
1. Read the learning objectives and faculty disclosures.
2. Participate in the activity.
3. Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie Inc., Celgene Corporation, Salix Pharmaceuticals, and Takeda Pharmaceuticals USA, Inc.

Off-label Disclosure Statement

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Disclaimer Statement

The opinions expressed during the enduring material activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions about the Activity

Accreditation Support:
Please contact the University of Cincinnati, Continuing Medical Education Department at uccme@uc.edu or by calling 513-558-7277.

Technical Support:
For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center.

Course Viewing

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above